About Glycostem Therapeutics

Glycostem Therapeutics is a Netherlands based lifescience company advancing the science of cellular immunotherapy by creating breakthroughs in the expansion and differentiation of hematopoietic stem cells.

Glycostem Therapeutics has developed a new and innovative cell culture system for the ex-vivo generation of clinically relevant amounts of NK-cells.   

Glycostem Therapeutics pursues an open project collaboration policy towards joint development of cellular immunotherapeutics for treatment of leukemia, lymphomas and other forms of cancer.   

Products

Product group 1
Prototype NK-cell and NK-cell progenitor products for R&D , (pre)clinical evaluations and intervention studies. 

With these prototype products exciting homing and killing results have already been achieved in pre-clinical experiments.  

In support of 3rd party R&D or (pre) clinical experiments, Glycostem Therapeutics offers dedicated guidance and tailor made service activities.  

Please let us know how we might help you in discovering the potential of ex-vivo generated NK-cells for your purpose.

Just call or mail us (see contacts)

Product group 2
Glycostem Basal Growth Medium GBGM® .

This is a new and innovative basal growth medium, specifically designed for the expansion and differentiation of hematopoietic stem and progenitor cells in "animal-component- free" culture systems.

Through the addition of selected components, such as cytokines, growth factors or human serum unprecedented culture conditions for human hematopoietic stem and progenitor cells, as well as other hematopoietic cells can be achieved.

GBGM® has an improved effect on cell survival and only minimal cellular delineation in expansion and differentiation experiments, as compared to other serum free media.

Exciting ex-vivo HSC expansion&differentiation results with GBGM® have been published by Spanholtz et al. in 2010 and 2011 on www.plosone.org , see Blog section of website. 

GBGM® is worldwide available via our distributor Clear Cell Technologies, see website
www.clearcelltechnologies.com